Skip to main content

Eli Lilly and Company diluted shares

  • LLY · NYSE
  • Pharmaceuticals
  • S&P 500
$1443.50+1.14%Close 13 Nov 2026 · Market value $1.36T

Eli Lilly and Company's diluted shares was 899M shares for fiscal year 2025 (the twelve months to 31 Dec 2025), down 0.5% from fiscal 2024.

In the third quarter of fiscal 2026 (the three months to 30 Sep 2026) it was 893M shares, down 0.6% from a year earlier.

From Eli Lilly and Company's annual and quarterly reports, compiled and checked by AapWire. Latest report filed 29 Oct 2026.

Fiscal 2025
899M
−0.5%
Q3 FY2026
893M
−0.6% on a year
Growth over 9 years
−1.8%
a year, FY 2016–FY 2025

Diluted shares by fiscal year

1.1BFY 20161.1BFY 2017−0.9%1.0BFY 2018−1.7%936MFY 2019−9.5%913MFY 2020−2.5%912MFY 2021−0.1%905MFY 2022−0.8%903MFY 2023−0.1%904MFY 2024+0.1%899MFY 2025−0.5%

Change on the year before, under each year. From FY 2016 to FY 2025, Eli Lilly and Company's diluted shares went from 1.1B shares to 899M shares, a compound annual change of −1.8%; the highest was 1.1B shares in FY 2016.

Eli Lilly and Company diluted shares, fiscal years
PeriodFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
Diluted shares1.1B1.1B1.0B936M913M912M905M903M904M899M
Period end31 Dec 201631 Dec 201731 Dec 201831 Dec 201931 Dec 202031 Dec 202131 Dec 202231 Dec 202331 Dec 202431 Dec 2025

Diluted shares by quarter

The last eight fiscal quarters. Each is compared with the same quarter a year earlier on the company's page.

Eli Lilly and Company diluted shares, fiscal quarters
PeriodQ4 FY2024Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025Q1 FY2026Q2 FY2026Q3 FY2026
Diluted shares903M901M900M899M898M896M894M893M
Period end31 Dec 202431 Mar 202530 Jun 202530 Sep 202531 Dec 202531 Mar 202630 Jun 202630 Sep 2026

How diluted shares is measured

Diluted shares is the weighted average number of shares outstanding in the period, counting the shares that options, warrants and convertible securities could add; it is the count earnings per share is divided by. Figures are read from the report the company filed and checked against accounting identities; one that does not pass is left blank rather than estimated. See data and methodology.

Eli Lilly and Company's other figures

Diluted shares of comparable companies

Everything on LLY, in the terminal.

Twenty years of history, operating KPIs and segments, guidance against results, valuation, insiders and holders, charts and alerts.